• Home
  •  / Ampio Pharmaceuticals

Ampio Pharmaceuticals

OverviewSuggest Edit

Ampio Pharmaceuticals is a development stage biopharmaceutical company focused on the discovery and development of novel therapies aimed at treating common inflammatory conditions for which there are limited treatment options. Its developing compounds serve significant medical needs in osteoarthritis, diabetic macular edema, and other prevalent, inflammatory diseases through a discovery and development platform.

TypePublic
Founded2010
HQEnglewood, CO, USMap
Websiteampiopharma.com

Recent NewsAll News

Latest Updates

Employees (est.) (Feb 2020)23(+5%)
Revenue (FY, 2013)$50 K
Share Price (Jan 2021)$1.5 (+11%)
Cybersecurity ratingCMore

Key People/Management at Ampio Pharmaceuticals

Michael Macaluso

Michael Macaluso

Chairman and Chief Executive Officer
Holli Cherevka

Holli Cherevka

Chief Operating Officer
David Bar

David Bar

CSO
Dan Stokely

Dan Stokely

Chief Financial Officer
Richard Giles

Richard Giles

Director
Philip Coelho

Philip Coelho

Director
Show more

Ampio Pharmaceuticals Office Locations

Ampio Pharmaceuticals has an office in Englewood
Englewood, CO, US (HQ)
373 Inverness Pkwy #200
Show all (1)

Ampio Pharmaceuticals Financials and Metrics

Ampio Pharmaceuticals Revenue

Ampio Pharmaceuticals's revenue was reported to be $50 k in FY, 2013
USD

Net income (Q3, 2020)

(3.4m)

Market capitalization (19-Jan-2021)

277.6m

Closing stock price (19-Jan-2021)

1.5

Cash (30-Sept-2020)

9.4m

EV

269.5m
Ampio Pharmaceuticals's current market capitalization is $277.6 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

18.8k50.0k50.0k

General and administrative expense

4.5m4.4m5.8m9.0m9.1m6.5m5.1m4.4m6.0m

R&D expense

6.6m7.5m18.3m22.4m15.0m10.4m12.6m

Operating expense total

11.1m11.9m24.1m31.3m24.0m16.9m5.1m49.5m18.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

6.3k12.5k12.5k12.5k12.5k12.5k12.5k21.4k21.4k21.4k163.0k466.0k

Cost of goods sold

87.9k37.3k

Gross profit

75.1k428.6k

Gross profit Margin, %

46%92%
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

11.4m17.7m26.3m50.3m27.0m4.9m8.2m7.6m6.5m

Prepaid Expenses

43.1k164.9k132.0k672.7k2.0m222.4k413.3k1.7m

Current Assets

11.4m17.8m26.4m51.3m29.2m5.4m8.4m8.0m8.3m

PP&E

76.2k59.3k1.3m9.9m9.3m6.8m6.0m4.7m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

8.4m7.0m8.3m6.8m20.3m16.5m12.5m32.1m78.2m65.6m56.8m43.3m36.8m35.4m11.1m6.5m7.4m2.3m4.9m1.8m7.5m4.7m8.7m5.2m12.8m8.0m2.4m4.8m9.4m

Accounts Receivable

722.2k

Prepaid Expenses

199.0k117.0k176.6k306.1k142.1k350.4k414.4k151.2k495.3k1.2m383.2k283.7k1.3m1.6m432.7k638.5k409.7k475.3k641.6k423.0k383.3k316.2k512.5k593.4k1.6m1.8m1.0m1.9m1.5m

Current Assets

8.6m7.1m8.5m7.1m20.4m16.9m12.9m32.2m79.0m67.1m58.2m43.8m38.4m37.2m11.7m7.5m8.3m3.0m5.6m2.3m7.9m5.0m9.2m5.8m14.4m9.9m3.4m6.8m10.8m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(18.4m)(11.6m)(24.5m)(39.0m)(33.7m)(19.2m)(51.9m)34.0m(13.6m)

Depreciation and Amortization

42.6k62.4k137.7k439.1k1.1m1.2m1.2m1.3m1.3m

Accounts Payable

166.2k570.5k699.5k1.0m(426.1k)(1.1m)2.1m(1.5m)2.7m

Cash From Operating Activities

(9.1m)(9.7m)(19.1m)(30.7m)(26.4m)(14.6m)(11.4m)(12.1m)(15.4m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(11.6m)(14.2m)(2.8m)(5.3m)(7.9m)(4.2m)(10.8m)(17.0m)(10.5m)(19.4m)(28.9m)(7.6m)(15.3m)(23.1m)(6.8m)(11.8m)(15.8m)(1.9m)(4.5m)(8.8m)22.0m26.7m32.5m(5.8m)(5.4m)(12.6m)(5.2m)(7.9m)(11.3m)

Depreciation and Amortization

11.4k27.0k15.6k31.2k46.8k18.5k57.8k97.3k41.2k83.1k209.8k231.0k461.6k816.1k305.5k611.1k916.6k303.5k607.2k910.7k300.9k621.2k968.0k365.1k736.2k975.3k295.0k591.0k885.0k

Accounts Payable

104.4k6.6k(224.2k)(272.5k)158.8k(31.3k)557.9k(34.3k)2.5m198.7k174.7k(1.8m)(857.0k)(988.4k)406.5k(435.4k)(657.5k)56.2k1.1m318.5k(292.6k)(610.4k)(1.3m)(46.1k)555.2k805.1k189.0k(1.8m)(2.4m)

Cash From Operating Activities

(3.5m)(5.0m)(3.1m)(5.2m)(7.1m)(3.6m)(8.7m)(14.1m)(8.5m)(18.2m)(25.0m)(7.0m)(12.4m)(18.7m)(4.9m)(9.5m)(12.0m)(2.6m)(5.7m)(8.8m)(3.6m)(6.6m)(9.8m)(2.4m)(5.9m)(10.6m)(4.6m)(9.1m)(11.8m)
show all
USDQ2, 2011

Financial Leverage

1.2 x
Show all financial metrics

Ampio Pharmaceuticals Operating Metrics

FY, 2016

Patent Applications

82

Patents Issued

121
Show all operating metrics

Ampio Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

C

78/100

Learn more about our premium products
SecurityScorecard logo

Ampio Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Ampio Pharmaceuticals Online and Social Media Presence

Ampio Pharmaceuticals's Trends

Embed Graph

Ampio Pharmaceuticals News and Updates

December 31, 2020

Thinking about buying stock in BioNano Genomics, Ampio Pharmaceuticals, TRACON Pharmaceuticals, eMagin Corp, or Matinas BioPharma?

NEW YORK, Dec. 31, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BNGO, AMPE, TCON, EMAN, and MTNB. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 23, 2020

Thinking about buying stock in CASI Pharmaceuticals, FuelCell Energy, Ampio Pharmaceuticals, Mohawk Group, or Perion Network?

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CASI, FCEL, AMPE, MWK, and PERI. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 14, 2020

Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?

NEW YORK, Dec. 14, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
December 11, 2020

Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?

NEW YORK, Dec. 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
November 05, 2020

Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results

ENGLEWOOD, Colo., Nov. 5, 2020 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, today, at 4:30pm EST, will provide an update and overview of its clinical...
September 21, 2020

Thinking about buying stock in Onconova Therapeutics, Norwegian Cruise Line, Ampio Pharmaceuticals, Delta Air Lines, or Plug Power?

NEW YORK, Sept. 21, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ONTX, NCLH, AMPE, DAL, and PLUG. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
Show more

Ampio Pharmaceuticals Blogs

January 14, 2021

Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled

ENGLEWOOD, Colo., January 14, 2021–Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies ... Read More The post Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is …
December 29, 2020

AMPIO RECEIVES FEEDBACK FROM THE FDA ON AMPIO’S PROPOSED MODIFICATIONS TO THE SPECIAL PROTOCOL ASSSESSMENT FOR AMPION TREATMENT OF SEVERE OSTEOARTHRITIS OF THE KNEE

ENGLEWOOD, Colo., December 29, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based ... Read More The post AMPIO RECEIVES FEEDBACK FROM THE FDA ON AMPIO’S PROPOSED MODIFICATIONS TO THE SPECIAL PROTOCOL ASS…
December 29, 2020

Q&A Regarding Feedback from FDA

QUESTION – Why do you consider the FDA response to our OAK proposal favorable? ANSWER – The FDA expressed their ... Read More The post Q&A Regarding Feedback from FDA appeared first on Ampio Pharmaceuticals.
December 23, 2020

Q&A with Dr. David Bar-Or on the COVID-19 Vaccines and the Variants

Does the vaccine change your DNA? Does the virus or infection change DNA? The vaccine is composed of mRNA encapsulated ... Read More The post Q&A with Dr. David Bar-Or on the COVID-19 Vaccines and the Variants appeared first on Ampio Pharmaceuticals.
December 17, 2020

Ampion Demonstrates Safety in COVID-19 Patients and Initiates Global Clinical Trial for Intravenous Ampion

ENGLEWOOD, Colo., December 17, 2020, /PRNewswire/ — Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology ... Read More The post Ampion Demonstrates Safety in COVID-19 Patients and Initiates Global Clinical Trial for Intravenous Ampi…
December 10, 2020

Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion

Agreements made with (i) Oldest and one of the top children’s hospitals in the United States and (ii) Prominent Research ... Read More The post Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion appeared first on Ampi…
Show more

 Ampio Pharmaceuticals Frequently Asked Questions

  • When was Ampio Pharmaceuticals founded?

    Ampio Pharmaceuticals was founded in 2010.

  • Who are Ampio Pharmaceuticals key executives?

    Ampio Pharmaceuticals's key executives are Michael Macaluso, Holli Cherevka and David Bar.

  • How many employees does Ampio Pharmaceuticals have?

    Ampio Pharmaceuticals has 23 employees.

  • Who are Ampio Pharmaceuticals competitors?

    Competitors of Ampio Pharmaceuticals include Biogen, Aimmune Therapeutics and GT Biopharma.

  • Where is Ampio Pharmaceuticals headquarters?

    Ampio Pharmaceuticals headquarters is located at 373 Inverness Pkwy #200, Englewood.

  • Where are Ampio Pharmaceuticals offices?

    Ampio Pharmaceuticals has an office in Englewood.

  • How many offices does Ampio Pharmaceuticals have?

    Ampio Pharmaceuticals has 1 office.